Autopsy report · NCT02005484

A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression

“Study terminated due to slow patient recruitment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 years 11 months after it had already started.
• Ran for about 4 years 1 month before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 6 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Gastric Cancer

Interventions

Trastuzumab

Participants

6

Sites

12

Countries

Austria, Germany

Trials that died the same way

• THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
  “Study terminated due to slow recruitment.” (93% match in meaning)
• Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
  “Slow recruitment; Study was terminated for futility reasons” (89% match in meaning)
• Long-term Extension Study of MCI-196
  “This study has been terminated because of insufficient patient recruitment.” (89% match in meaning)
• Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
  “Study was terminated early because of slow recruitment” (88% match in meaning)
• Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
  “The study was terminated due to difficulty in recruiting patients.” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.